Bluebird Bio
HHS OIG Issues Unfavorable Opinion on Gene Therapy Developer's Fertility Preservation Program
Without more data on the risk of abuse associated with these programs, the agency won't provide immunity to drugmakers offering to pay for fertility services.
Gilead, Arcellx Outline Plans for Phase III Anito-Cel Multiple Myeloma Trial
The partners will compare the activity of the BCMA-directed autologous CAR T-cell therapy against standard treatment in refractory patients.
First Sickle Cell Disease Patient Prepares to Get Bluebird Bio's Lyfgenia
A patient at Children's National Hospital in Washington, D.C., will be the first to receive the gene therapy outside of a clinical trial.
FDA Approves Bristol Myers Squibb, 2seventy bio's Abecma in Earlier-Line Multiple Myeloma
Regulators acted in concert with the advisory committee that last month voted in favor of the CAR T-cell therapy's benefit.
Bluebird Bio Enters Into $175M Loan Deal
The firm can borrow the funds over four tranches and use it to market its FDA-approved gene therapies including the sickle cell therapy Lyfgenia.